Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
Tubocurarine chloride is a neuromuscular blocking agent administered by injection, used as an adjunct to anesthesia to facilitate intubation and surgical relaxation. It works by competitively blocking acetylcholine at the neuromuscular junction, causing paralysis. This legacy small-molecule drug has been a cornerstone of perioperative anesthesia for nearly 80 years.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and likely reduced team investment or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on tubocurarine chloride offers limited career growth given its approaching loss of exclusivity, mature market position, and zero linked job openings. This role is best suited for professionals managing legacy portfolios or transitioning products, not for those seeking high-visibility launches or commercial expansion.
Worked on TUBOCURARINE CHLORIDE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.